Previous Close | 1.7700 |
Open | 1.7400 |
Bid | 1.5000 x 1200 |
Ask | 1.7400 x 1000 |
Day's Range | 1.6700 - 1.7900 |
52 Week Range | 1.5700 - 5.4300 |
Volume | |
Avg. Volume | 39,590 |
Market Cap | 43.172M |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.8960 |
Earnings Date | Nov 02, 2022 - Nov 07, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Subscribe to Yahoo Finance Plus to view Fair Value for ORGS
Secures Funding from Metalmark Capital Partners to Drive Growth Orgenesis to Host Conference Call Today, August 16, 2022 at 11 AM Eastern Time GERMANTOWN, Md., Aug. 16, 2022 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies (CGT), today provided a business update for second quarter ending June 30, 2022. Vered Caplan, CEO of Orgenesis, said, “We are progressing with our transit
GERMANTOWN, Md., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies, today announced that it will host a conference call at 11:00 AM Eastern Time on Tuesday, August 16, 2022 to discuss the company’s corporate progress and other developments. The conference call will be available via telephone by dialing toll free 888-506-0062 for U.S. callers or +1 973-528-0011 fo
GERMANTOWN, Md., May 24, 2022 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies, today provided a business update for first quarter ended March 31, 2022. Recent highlights: Expanded POCare with Johns Hopkins University through creation of the Maryland Center for Cell Therapy ManufacturingReached milestone in collaboration with Hospital Infantil Universitario Niño Jesús in Madr